Harrow (HROW) reported $272M in revenue for fiscal 2025, +36.4% year on year. That ranks #2534 by revenue among 2853 SEC filers and #256 in Healthcare. It posted a net loss of −$5.1M for the same year. Revenue has grown 33.6% a year on average since 2017 ($26.8M then). The fiscal 2025 balance sheet shows $399M in total assets, $72.9M in cash and $250M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $272M | +36.4% | FY20252025-12-31 |
| Gross profitGrossProfit | $204M | +35.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $30.5M | +245.9% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$5.1M | +$12.3M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $43.9M | +$66.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $887,000 | −44.4% | FY20252025-12-31 |
| Total assetsAssets | $399M | +2.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $52.4M | −24.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $72.9M | +54.4% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $250M | −4.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $44.2M | −$27.6M | Open → |
| Q2 20262026-06-30 | $70.7M | −$17.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Harrow, Inc.
- Ticker
- HROW
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001360214
Filings
- 10-QAug 10, 2026Open filing →
- 10-QMay 11, 2026Open filing →
- 10-KMar 2, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Aurinia PharmaceuticalsAUPH | $283M | $287M |
| Adaptive BiotechnologiesADPT | $277M | −$59.5M |
| VericelVCEL | $276M | $16.5M |
| HarrowHROW | $272M | −$5.1M |
| Viemed HealthcareVMD | $270M | $15.4M |
| Vireo GrowthVREOF | $269M | −$68.1M |
| Ligand PharmaceuticalsLGND | $268M | $124M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Harrow — Key figures |url=https://companiesranked.com/en/company/harrow |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Harrow — Key figures. CompaniesRanked. https://companiesranked.com/en/company/harrowBibTeX
@misc{companiesranked-en-company-harrow-2026,
author = {{CompaniesRanked}},
title = {{Harrow — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/harrow}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001493152-26-008562 · March 2, 2026
{{cite web |title=Harrow — Key figures — 10-K (0001493152-26-008562) |url=https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/form10-k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.